Suppression	O
of	O
NF-kappaB	B-protein
activation	O
in	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
by	O
supernatant	O
fluid	O
from	O
human	O
renal	O
cell	O
carcinomas	O
.	O

T	B-cell_type
lymphocytes	I-cell_type
from	O
patients	O
with	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
show	O
reduced	O
immune	O
function	O
and	O
impaired	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
,	O
NF-kappaB	B-protein
.	O

We	O
determined	O
the	O
mechanism	O
of	O
NF-kappaB	B-protein
suppression	O
in	O
T	B-cell_type
cells	I-cell_type
of	O
RCC	O
patient	O
and	O
determined	O
whether	O
supernatant	O
fluid	O
from	O
RCC	O
explants	O
(	O
RCC-S	O
)	O
induced	O
the	O
same	O
phenotype	O
of	O
NF-kappaB	B-protein
suppression	O
in	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
that	O
is	O
observed	O
in	O
patient	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
pattern	O
of	O
kappaB	B-protein
-binding	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
of	O
RCC	O
patient	O
was	O
altered	O
as	O
compared	O
to	O
that	O
seen	O
in	O
T	B-cell_type
cells	I-cell_type
obtained	O
from	O
normal	O
volunteers	O
.	O

In	O
some	O
patients	O
,	O
no	O
activation	O
of	O
RelA/NFkappaB1	B-protein
-binding	O
activity	O
was	O
detectable	O
,	O
while	O
in	O
others	O
kappaB	B-protein
-binding	O
activity	O
was	O
modestly	O
induced	O
but	O
the	O
duration	O
was	O
reduced	O
.	O

IkappaBalpha	B-protein
was	O
degraded	O
normally	O
following	O
stimulation	O
in	O
both	O
normal	O
controls	O
and	O
T	B-cell_type
cells	I-cell_type
from	O
RCC	O
patients	O
.	O

RCC-S	O
did	O
not	O
alter	O
the	O
cytoplasmic	O
levels	O
of	O
RelA	B-protein
and	O
NF-kappaB1	B-protein
but	O
did	O
suppress	O
their	O
nuclear	O
localization	O
and	O
inhibited	O
the	O
activation	O
of	O
RelA/NF-kappaB1	B-protein
binding	I-protein
complexes	I-protein
.	O

These	O
results	O
show	O
that	O
RCC-S	O
can	O
induce	O
in	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
the	O
same	O
phenotype	O
of	O
impaired	O
NF-kappaB	B-protein
activation	O
that	O
is	O
detected	O
in	O
T	B-cell_type
cells	I-cell_type
of	O
RCC	O
patient	O
.	O

It	O
also	O
appears	O
that	O
NF-kappaB	B-protein
suppression	O
by	O
RCC-S	O
may	O
contribute	O
to	O
the	O
immunosuppression	O
of	O
host	O
immunity	O
.	O

J	NULL
Korean	NULL
Med	NULL
Sci	NULL
1999	NULL
;	NULL
14	NULL
:	NULL
299-303	NULL
ISSN	NULL
1011-8934	NULL
Copyright	NULL
©	NULL
The	NULL
Korean	NULL
Academy	NULL
of	NULL
Medical	NULL
Sciences	NULL
Suppression	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
Activation	NULL
in	NULL
Normal	NULL
T	NULL
Cells	NULL
by	NULL
Supernatant	NULL
Fluid	NULL
from	NULL
Human	NULL
Renal	NULL
Cell	NULL
Carcinomas	NULL
T	NULL
lymphocytes	NULL
from	NULL
patients	NULL
with	NULL
renal	NULL
cell	NULL
carcinoma	NULL
(	NULL
RCC	NULL
)	NULL
show	NULL
reduced	NULL
immune	NULL
function	NULL
and	NULL
impaired	NULL
activation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
,	NULL
We	NULL
determined	NULL
the	NULL
mechanism	NULL
of	NULL
suppression	NULL
in	NULL
T	NULL
cells	NULL
of	NULL
RCC	NULL
patient	NULL
and	NULL
determined	NULL
whether	NULL
supernatant	NULL
fluid	NULL
from	NULL
RCC	NULL
explants	NULL
(	NULL
RCC-S	NULL
)	NULL
induced	NULL
the	NULL
same	NULL
phenotype	NULL
of	NULL
suppression	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
that	NULL
is	NULL
observed	NULL
in	NULL
patient	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
pattern	NULL
of	NULL
xB-binding	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
of	NULL
RCC	NULL
patient	NULL
was	NULL
altered	NULL
as	NULL
compared	NULL
to	NULL
that	NULL
seen	NULL
in	NULL
T	NULL
cells	NULL
obtained	NULL
from	NULL
normal	NULL
volunteers	NULL
.	NULL

In	NULL
some	NULL
patients	NULL
,	NULL
no	NULL
activation	NULL
of	NULL
RelA/NFxB1-binding	NULL
activity	NULL
was	NULL
detectable	NULL
,	NULL
while	NULL
in	NULL
others	NULL
xB-binding	NULL
activity	NULL
was	NULL
modestly	NULL
induced	NULL
but	NULL
the	NULL
duration	NULL
was	NULL
reduced	NULL
.	NULL

IxBa	NULL
was	NULL
degraded	NULL
normally	NULL
following	NULL
stimulation	NULL
in	NULL
both	NULL
normal	NULL
controls	NULL
and	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
.	NULL

RCC-S	NULL
did	NULL
not	NULL
alter	NULL
the	NULL
cytoplasmic	NULL
levels	NULL
of	NULL
RelA	NULL
and	NULL
NF-	NULL
«	NULL
B1	NULL
but	NULL
did	NULL
suppress	NULL
their	NULL
nuclear	NULL
localization	NULL
and	NULL
inhibited	NULL
the	NULL
activation	NULL
of	NULL
«	NULL
B1	NULL
binding	NULL
complexes	NULL
.	NULL

These	NULL
results	NULL
show	NULL
that	NULL
RCC-S	NULL
can	NULL
induce	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
the	NULL
same	NULL
phenotype	NULL
of	NULL
impaired	NULL
NF-xB	NULL
activation	NULL
that	NULL
is	NULL
detected	NULL
in	NULL
T	NULL
cells	NULL
of	NULL
RCC	NULL
patient	NULL
.	NULL

It	NULL
also	NULL
appears	NULL
that	NULL
NF-kB	NULL
Hyung	NULL
Jin	NULL
Kim	NULL
,	NULL
Jong	NULL
Kwan	NULL
Park	NULL
,	NULL
Young	NULL
Gon	NULL
Kim	NULL
Department	NULL
of	NULL
Urology	NULL
,	NULL
Institute	NULL
for	NULL
Medical	NULL
Science	NULL
,	NULL
Chonbuk	NULL
National	NULL
University	NULL
Medical	NULL
School	NULL
,	NULL
Chonju	NULL
,	NULL
Korea	NULL
Received	NULL
:	NULL
8	NULL
October	NULL
1998	NULL
Accepted	NULL
:	NULL
17	NULL
December	NULL
1998	NULL
Address	NULL
for	NULL
correspondence	NULL
Hyung	NULL
Jin	NULL
Kim	NULL
,	NULL
M.D	NULL
.	NULL

Department	NULL
of	NULL
Urology	NULL
,	NULL
Chonbuk	NULL
National	NULL
University	NULL
Hospital	NULL
,	NULL
634-18	NULL
,	NULL
Keurnam-dong	NULL
,	NULL
immunity	NULL
.	NULL

INTRODUCTION	NULL
Among	NULL
renal	NULL
cell	NULL
carcinoma	NULL
(	NULL
RCC	NULL
)	NULL
patients	NULL
,	NULL
30	NULL
%	NULL
have	NULL
metastases	NULL
at	NULL
the	NULL
time	NULL
of	NULL
diagnosis	NULL
.	NULL

Two-year	NULL
survival	NULL
rate	NULL
of	NULL
RCC	NULL
patient	NULL
is	NULL
10-20	NULL
%	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Metastatic	NULL
RCC	NULL
is	NULL
ordinarily	NULL
resistant	NULL
to	NULL
both	NULL
radiation	NULL
therapy	NULL
and	NULL
chemotherapy	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
development	NULL
of	NULL
immuno-therapy	NULL
,	NULL
including	NULL
interfefon-	NULL
@	NULL
,	NULL
interleukin-2	NULL
and	NULL
inter-leukin-12	NULL
has	NULL
resulted	NULL
in	NULL
improved	NULL
response	NULL
rates	NULL
in	NULL
metastatic	NULL
RCC	NULL
,	NULL
the	NULL
treatment	NULL
of	NULL
metastatic	NULL
RCC	NULL
remains	NULL
difficult	NULL
with	NULL
less	NULL
than	NULL
25	NULL
%	NULL
of	NULL
patients	NULL
responding	NULL
favorably	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Several	NULL
mechanisms	NULL
contribute	NULL
to	NULL
the	NULL
immune	NULL
unresponsiveness	NULL
of	NULL
cancer	NULL
patients	NULL
,	NULL
including	NULL
immune	NULL
suppression	NULL
directly	NULL
induced	NULL
by	NULL
the	NULL
cancer	NULL
through	NULL
its	NULL
production	NULL
of	NULL
soluble	NULL
immune	NULL
suppressive	NULL
factors	NULL
(	NULL
5	NULL
)	NULL
.	NULL

T	NULL
cells	NULL
represent	NULL
an	NULL
important	NULL
component	NULL
of	NULL
the	NULL
host	NULL
immune	NULL
response	NULL
against	NULL
human	NULL
tumor	NULL
cells	NULL
.	NULL

The	NULL
impairment	NULL
of	NULL
T	NULL
cell	NULL
function	NULL
and	NULL
signaling	NULL
pathways	NULL
observed	NULL
in	NULL
cancer	NULL
patients	NULL
may	NULL
hinder	NULL
the	NULL
development	NULL
of	NULL
T	NULL
cell	NULL
immunity	NULL
and	NULL
reduce	NULL
the	NULL
effectiveness	NULL
of	NULL
immunotherapy	NULL
.	NULL

NF-4B	NULL
is	NULL
important	NULL
to	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
regulates	NULL
the	NULL
inducible	NULL
expression	NULL
of	NULL
a	NULL
large	NULL
number	NULL
of	NULL
genes	NULL
necessary	NULL
for	NULL
the	NULL
development	NULL
of	NULL
T	NULL
cell	NULL
suppression	NULL
by	NULL
RCC-S	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
immunosuppression	NULL
of	NULL
host	NULL
Key	NULL
Words	NULL
:	NULL
Transcription	NULL
factors	NULL
;	NULL
T-lymphocytes	NULL
;	NULL
Kiahey	NULL
neoplasms	NULL
;	NULL
Proteins	NULL
,	NULL
NF-	NULL
xB	NULL
299	NULL
Chonju	NULL
561-712	NULL
,	NULL
Korea	NULL
Tel	NULL
:	NULL
+82.652-250-1568	NULL
,	NULL
Fax	NULL
:	NULL
+82.652-250-1564	NULL
E-mail	NULL
:	NULL
hjkim	NULL
@	NULL
moak.chonbuk.ac.kr	NULL
*This	NULL
study	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
research	NULL
grant	NULL
from	NULL
Chonbuk	NULL
National	NULL
University	NULL
Hospital	NULL
.	NULL

immunity	NULL
.	NULL

The	NULL
family	NULL
of	NULL
proteins	NULL
is	NULL
composed	NULL
of	NULL
p105/p50	NULL
p65	NULL
(	NULL
RelA	NULL
)	NULL
,	NULL
p100/p52	NULL
(	NULL
NF-kB2	NULL
)	NULL
,	NULL
c-Rel	NULL
and	NULL
RelB	NULL
which	NULL
bind	NULL
the	NULL
5B	NULL
sequence	NULL
motif	NULL
in	NULL
homo	NULL
of	NULL
heterodimeric	NULL
form	NULL
(	NULL
6-10	NULL
)	NULL
.	NULL

NF-KB	NULL
is	NULL
present	NULL
in	NULL
an	NULL
inactive	NULL
form	NULL
in	NULL
the	NULL
cytoplasm	NULL
of	NULL
T	NULL
cells	NULL
through	NULL
interaction	NULL
with	NULL
inhibitory	NULL
proteins	NULL
,	NULL
collectively	NULL
termed	NULL
IxkBs	NULL
.	NULL

kBq	NULL
inhibits	NULL
both	NULL
DNA	NULL
binding	NULL
activity	NULL
and	NULL
nuclear	NULL
localization	NULL
of	NULL
RelA	NULL
and	NULL
c-Rel	NULL
proteins	NULL
(	NULL
6	NULL
,	NULL
11	NULL
)	NULL
.	NULL

The	NULL
principle	NULL
steps	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
NF-kB	NULL
involve	NULL
the	NULL
dissociation	NULL
of	NULL
dimeric	NULL
forms	NULL
containing	NULL
RelA	NULL
,	NULL
c-Rel	NULL
and	NULL
from	NULL
IxBa	NULL
@	NULL
after	NULL
phosphorylation	NULL
and	NULL
subsequent	NULL
degradation	NULL
of	NULL
I	NULL
xBa	NULL
@	NULL
(	NULL
6	NULL
,	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

We	NULL
determined	NULL
the	NULL
mechanism	NULL
of	NULL
NF-4B	NULL
suppression	NULL
in	NULL
T	NULL
cells	NULL
of	NULL
RCC	NULL
patient	NULL
and	NULL
determined	NULL
RCC-S	NULL
induced	NULL
suppression	NULL
of	NULL
NF-4B	NULL
activation	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
observed	NULL
in	NULL
T	NULL
cells	NULL
of	NULL
RCC	NULL
patient	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
culture	NULL
and	NULL
isolation	NULL
of	NULL
T	NULL
cells	NULL
Peripheral	NULL
blood	NULL
was	NULL
obtained	NULL
from	NULL
patients	NULL
with	NULL
con	NULL
300	NULL
firmed	NULL
diagnosis	NULL
of	NULL
renal	NULL
cell	NULL
carcinoma	NULL
and	NULL
healthy	NULL
volunteers	NULL
.	NULL

Tumor	NULL
tissue	NULL
was	NULL
obtained	NULL
from	NULL
RCC	NULL
patients	NULL
and	NULL
used	NULL
to	NULL
make	NULL
tumor	NULL
supernatants	NULL
.	NULL

Normal	NULL
T	NULL
cells	NULL
were	NULL
used	NULL
as	NULL
control	NULL
and	NULL
compared	NULL
to	NULL
patient	NULL
T	NULL
cells	NULL
.	NULL

Normal	NULL
T	NULL
cells	NULL
from	NULL
healthy	NULL
donors	NULL
were	NULL
used	NULL
for	NULL
culturing	NULL
with	NULL
tumor	NULL
supernatants	NULL
.	NULL

Peripheral	NULL
blood	NULL
lymphocytes	NULL
(	NULL
PBL	NULL
)	NULL
were	NULL
isolated	NULL
from	NULL
healthy	NULL
volunteers	NULL
and	NULL
RCC	NULL
patients	NULL
.	NULL

T	NULL
cells	NULL
were	NULL
purified	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
13	NULL
,	NULL
14	NULL
)	NULL
:	NULL
PBL	NULL
were	NULL
subjected	NULL
to	NULL
Ficoll-Hypaque	NULL
(	NULL
Pharmacia	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
,	NULL
U.S.A.	NULL
)	NULL
density	NULL
gradient	NULL
centrifu-gation	NULL
and	NULL
then	NULL
depleted	NULL
of	NULL
macrophages	NULL
,	NULL
B	NULL
cells	NULL
and	NULL
NK	NULL
cells	NULL
by	NULL
negative	NULL
selection	NULL
using	NULL
magnetic	NULL
separation	NULL
with	NULL
microbeads	NULL
coated	NULL
with	NULL
antibodies	NULL
to	NULL
CD14	NULL
,	NULL
CD16	NULL
and	NULL
CD19	NULL
(	NULL
Miltenyi	NULL
Biotec	NULL
Inc.	NULL
,	NULL
Sunnyvale	NULL
,	NULL
CA	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

To	NULL
obtain	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
T	NULL
cells	NULL
(	NULL
5	NULL
X	NULL
10	NULL
``	NULL
/mLl	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
absence	NULL
and	NULL
presence	NULL
of	NULL
stimulus	NULL
for	NULL
various	NULL
lengths	NULL
of	NULL
times	NULL
.	NULL

The	NULL
medium	NULL
used	NULL
was	NULL
RPMI1640	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

PMA	NULL
(	NULL
20	NULL
ng/mL	NULL
)	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
,	NULL
U.S.A.	NULL
)	NULL
plus	NULL
ionomycin	NULL
(	NULL
0.75	NULL
ug/ml	NULL
)	NULL
(	NULL
Sigma	NULL
)	NULL
or	NULL
cross-linked	NULL
anti-CD3	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
(	NULL
Ortho	NULL
Biotech	NULL
,	NULL
Rariton	NULL
,	NULL
NJ	NULL
,	NULL
U.S.A.	NULL
)	NULL
plus	NULL
IL-2	NULL
(	NULL
1000	NULL
IU	NULL
)	NULL
(	NULL
Hoffman	NULL
LaRoche	NULL
,	NULL
Nutley	NULL
,	NULL
NJ	NULL
,	NULL
U.S.A.	NULL
)	NULL
were	NULL
used	NULL
as	NULL
stimulus	NULL
.	NULL

Preparation	NULL
of	NULL
tumor	NULL
supernatants	NULL
To	NULL
generate	NULL
tumof	NULL
supernatant	NULL
fluid	NULL
,	NULL
tumot	NULL
tissues	NULL
from	NULL
primary	NULL
renal	NULL
cell	NULL
carcinoma	NULL
were	NULL
obtained	NULL
from	NULL
patients	NULL
undergoing	NULL
radical	NULL
nephrectomy	NULL
.	NULL

3	NULL
X3	NULL
mm	NULL
explants	NULL
were	NULL
made	NULL
from	NULL
tumots	NULL
using	NULL
a	NULL
No	NULL
.	NULL

10	NULL
Bard-Parker	NULL
scalpel	NULL
and	NULL
incubated	NULL
overnight	NULL
in	NULL
RPMI1640	NULL
medium	NULL
.	NULL

Thereafter	NULL
,	NULL
1g	NULL
of	NULL
3X3	NULL
mm	NULL
explants	NULL
were	NULL
placed	NULL
into	NULL
a	NULL
T-75	NULL
flask	NULL
with	NULL
15	NULL
mL	NULL
of	NULL
Dulbecco	NULL
's	NULL
Modified	NULL
Eagles	NULL
Medium	NULL
without	NULL
additional	NULL
supple-ments	NULL
.	NULL

After	NULL
three	NULL
days	NULL
of	NULL
culture	NULL
at	NULL
37°C	NULL
with	NULL
95	NULL
%	NULL
air	NULL
and	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
the	NULL
supernatant	NULL
fluid	NULL
was	NULL
harvested	NULL
,	NULL
filtered	NULL
and	NULL
stored	NULL
at	NULL
-70	NULL
°C	NULL
until	NULL
use	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
effect	NULL
of	NULL
tumor-detived	NULL
soluble	NULL
products	NULL
on	NULL
normal	NULL
T	NULL
cells	NULL
,	NULL
T	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
complete	NULL
RPMI1640	NULL
with	NULL
and	NULL
without	NULL
RCC-S	NULL
.	NULL

The	NULL
supernatant	NULL
fluid	NULL
was	NULL
added	NULL
to	NULL
T	NULL
cell	NULL
cultures	NULL
,	NULL
using	NULL
20-50	NULL
%	NULL
dilution	NULL
.	NULL

Preparation	NULL
of	NULL
cytoplasmic	NULL
and	NULL
nuclear	NULL
extracts	NULL
Cytoplasmic	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
according	NULL
to	NULL
Schreiber	NULL
et	NULL
al	NULL
.	NULL

(	NULL
15	NULL
)	NULL
with	NULL
minor	NULL
modifications	NULL
.	NULL

T	NULL
cells	NULL
(	NULL
10	NULL
X	NULL
10	NULL
%	NULL
/mL	NULL
)	NULL
were	NULL
harvested	NULL
and	NULL
washed	NULL
with	NULL
cold	NULL
PBS	NULL
,	NULL
and	NULL
then	NULL
sedimented	NULL
by	NULL
centrifugation	NULL
.	NULL

The	NULL
cell	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
150	NULL
L	NULL
of	NULL
buffer	NULL
A	NULL
(	NULL
10	NULL
mM	NULL
HEPES	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
10	NULL
mM	NULL
KCI	NULL
,	NULL
0.1	NULL
mM	NULL
EDTA	NULL
,	NULL
0.1	NULL
raM	NULL
EGTA	NULL
,	NULL
1	NULL
maM	NULL
DTT	NULL
,	NULL
100	NULL
ug/ml	NULL
PMSF	NULL
,	NULL
2	NULL
ug/ml	NULL
aprotinin	NULL
,	NULL
2	NULL
g/mL	NULL
leupeptin	NULL
,	NULL
100	NULL
pg/mL	NULL
Pefabloc	NULL
and	NULL
100	NULL
ug/ml	NULL
chymostatin	NULL
)	NULL
by	NULL
gentle	NULL
pipetting	NULL
.	NULL

The	NULL
cells	NULL
H.J	NULL
.	NULL

Kim	NULL
,	NULL
J.K.	NULL
Park	NULL
,	NULL
Y.G	NULL
.	NULL

Kim	NULL
were	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
15	NULL
min	NULL
and	NULL
then	NULL
10	NULL
ul	NULL
of	NULL
10	NULL
%	NULL
Nonidet	NULL
P-40	NULL
solution	NULL
(	NULL
Sigma	NULL
)	NULL
was	NULL
added	NULL
and	NULL
centrifuged	NULL
.	NULL

The	NULL
supernatant	NULL
fluid	NULL
containing	NULL
the	NULL
cytoplasmic	NULL
extracts	NULL
was	NULL
aliquoted	NULL
.	NULL

Pelleted	NULL
nuclei	NULL
were	NULL
resuspended	NULL
in	NULL
50	NULL
L	NULL
of	NULL
buffer	NULL
C	NULL
(	NULL
25	NULL
%	NULL
glycerol	NULL
,	NULL
20	NULL
mM	NULL
HEPES	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
0.4	NULL
M	NULL
NaCl	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
EGTA	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
100	NULL
ug/ml	NULL
PMSF	NULL
,	NULL
2	NULL
ug/ml	NULL
aprotinin	NULL
,	NULL
2	NULL
g/mL	NULL
leupeptin	NULL
,	NULL
100	NULL
ug/ml	NULL
Pefabloc	NULL
and	NULL
100	NULL
ug/mal	NULL
chymostatin	NULL
)	NULL
.	NULL

After	NULL
mixing	NULL
at	NULL
4°C	NULL
for	NULL
20	NULL
min	NULL
and	NULL
centrifuge	NULL
,	NULL
supernatants	NULL
containing	NULL
the	NULL
nuclear	NULL
proteins	NULL
were	NULL
taken	NULL
and	NULL
stored	NULL
at	NULL
-70°C	NULL
.	NULL

Protein	NULL
concentration	NULL
was	NULL
measured	NULL
with	NULL
a	NULL
commercial	NULL
kit	NULL
(	NULL
Pierce	NULL
BCA	NULL
kit	NULL
,	NULL
Rockford	NULL
,	NULL
IL	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
Protein	NULL
samples	NULL
(	NULL
5-10	NULL
ug	NULL
)	NULL
were	NULL
mixed	NULL
with	NULL
equal	NULL
volume	NULL
of	NULL
2X	NULL
Laemmli	NULL
sample	NULL
buffer	NULL
,	NULL
boiled	NULL
and	NULL
resolved	NULL
by	NULL
electrophoresis	NULL
in	NULL
10	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate-poly-acrylamide	NULL
gels	NULL
.	NULL

The	NULL
proteins	NULL
were	NULL
transferred	NULL
from	NULL
the	NULL
gel	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
blocked	NULL
by	NULL
incubating	NULL
in	NULL
5	NULL
%	NULL
nonfat	NULL
dry	NULL
milk	NULL
in	NULL
TBST	NULL
overnight	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
sequentially	NULL
incubated	NULL
with	NULL
specific	NULL
antibody	NULL
(	NULL
two	NULL
hr	NULL
for	NULL
anti-lkBa	NULL
@	NULL
and	NULL
anti-c-Rel	NULL
,	NULL
one	NULL
hr	NULL
for	NULL
anti-RelA	NULL
and	NULL
and	NULL
then	NULL
with	NULL
horseradish	NULL
peroxidase-conjugated	NULL
donkey	NULL
anti-rab-bit	NULL
IgG	NULL
(	NULL
Amersham	NULL
,	NULL
Chicago	NULL
,	NULL
IL	NULL
,	NULL
U.S.A.	NULL
;	NULL
1:2000	NULL
dilution	NULL
in	NULL
TBST	NULL
)	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
washed	NULL
with	NULL
TBST	NULL
and	NULL
specific	NULL
immune	NULL
complexes	NULL
were	NULL
detected	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
Dupont	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
EMSA	NULL
was	NULL
performed	NULL
using	NULL
nuclear	NULL
extracts	NULL
obtained	NULL
at	NULL
various	NULL
times	NULL
after	NULL
stimulation	NULL
with	NULL
either	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
of	NULL
cross-linked	NULL
anti-CD3	NULL
plus	NULL
IL-2	NULL
.	NULL

Nuclear	NULL
extracts	NULL
(	NULL
5-10	NULL
ug	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
a	NULL
25	NULL
pL	NULL
total	NULL
reaction	NULL
volume	NULL
containing	NULL
20	NULL
mM	NULL
HEPES	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
80	NULL
mM	NULL
NaCl	NULL
,	NULL
0.1	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
8	NULL
%	NULL
glycerol	NULL
and	NULL
2	NULL
uL	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Pharmacia	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
,	NULL
U.S.A.	NULL
)	NULL
for	NULL
15	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
reaction	NULL
mixture	NULL
was	NULL
then	NULL
incubated	NULL
with	NULL
radiolabeled	NULL
oligonucleotide	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
cpm	NULL
)	NULL
for	NULL
20	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
analyzed	NULL
by	NULL
electrophoresis	NULL
in	NULL
6	NULL
%	NULL
non-denaturing	NULL
polyacrylamide	NULL
gel	NULL
with	NULL
0.25X	NULL
TBE	NULL
buffer	NULL
(	NULL
22.3	NULL
mM	NULL
Tris	NULL
,	NULL
22.2	NULL
mM	NULL
boric	NULL
acid	NULL
,	NULL
0.5	NULL
mM	NULL
EDTA	NULL
)	NULL
The	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
analyzed	NULL
by	NULL
autoradiography	NULL
.	NULL

An	NULL
oligonucleotide	NULL
corte-sponding	NULL
to	NULL
KB	NULL
element	NULL
from	NULL
the	NULL
IL-2R	NULL
@	NULL
gene	NULL
was	NULL
prepared	NULL
by	NULL
using	NULL
an	NULL
Applied	NULL
Biosystems	NULL
oligonucleotide	NULL
synthesizer	NULL
(	NULL
model	NULL
381A	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
oligonucleotide	NULL
was	NULL
:	NULL
5-CAACGGCAGGGGAATCTCCCTCTC-CTT-3	NULL
'	NULL
.	NULL

The	NULL
underlined	NULL
sequence	NULL
represents	NULL
the	NULL
kB	NULL
motif	NULL
.	NULL

Impaired	NULL
NF-xB	NULL
Activation	NULL
in	NULL
RCC	NULL
Patients	NULL
Normal	NULL
PBL	NULL
RCC	NULL
PBL	NULL
22	NULL
RCC	NULL
PBL	NULL
25	NULL
PMA/lonomycin	NULL
_	NULL
0	NULL
0.5	NULL
2.0	NULL
0	NULL
0.5	NULL
20	NULL
0	NULL
0.5	NULL
20	NULL
(	NULL
Hr	NULL
)	NULL
M*	NULL
!	NULL

C1	NULL
-	NULL
»	NULL
C2	NULL
-	NULL
»	NULL
H	NULL
,	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Analysis	NULL
of	NULL
stimulus-induced	NULL
kB	NULL
binding	NULL
activity	NULL
in	NULL
normal	NULL
and	NULL
patient	NULL
T	NULL
cells	NULL
by	NULL
EMSA	NULL
.	NULL

Normal	NULL
PBL	NULL
,	NULL
normal	NULL
T	NULL
cells	NULL
;	NULL
RCC	NULL
PBL	NULL
,	NULL
T	NULL
cells	NULL
of	NULL
RCC	NULL
patient	NULL
.	NULL

<	NULL
but	NULL
RESULTS	NULL
kB-binding	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
T	NULL
cells	NULL
from	NULL
normal	NULL
donors	NULL
and	NULL
RCC	NULL
patients	NULL
were	NULL
stimulated	NULL
with	NULL
PMA/ionomycin	NULL
and	NULL
activity	NULL
of	NULL
those	NULL
cells	NULL
were	NULL
analyzed	NULL
by	NULL
EMSA	NULL
.	NULL

In	NULL
normal	NULL
T	NULL
cells	NULL
,	NULL
stimulation	NULL
with	NULL
PMA/ionomycin	NULL
resulted	NULL
in	NULL
the	NULL
appearance	NULL
of	NULL
two	NULL
distinct	NULL
«	NULL
B	NULL
motif-specific	NULL
DNA-binding	NULL
activities	NULL
(	NULL
designated	NULL
C1	NULL
and	NULL
C2	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Both	NULL
complexes	NULL
were	NULL
observed	NULL
within	NULL
30	NULL
min	NULL
of	NULL
stimulation	NULL
and	NULL
remained	NULL
elevated	NULL
for	NULL
at	NULL
least	NULL
two	NULL
hr	NULL
.	NULL

In	NULL
six	NULL
of	NULL
patient-derived	NULL
T	NULL
cells	NULL
(	NULL
n=10	NULL
)	NULL
,	NULL
the	NULL
C1	NULL
complex	NULL
was	NULL
not	NULL
detectable	NULL
.	NULL

In	NULL
T	NULL
cells	NULL
obtained	NULL
from	NULL
the	NULL
other	NULL
four	NULL
patients	NULL
,	NULL
the	NULL
C1	NULL
activity	NULL
was	NULL
observed	NULL
after	NULL
30	NULL
min	NULL
of	NULL
stimulation	NULL
but	NULL
returned	NULL
to	NULL
basal	NULL
levels	NULL
in	NULL
two	NULL
hr	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
patient	NULL
T	NULL
cells	NULL
showed	NULL
consti-tutive	NULL
expression	NULL
of	NULL
the	NULL
C2	NULL
complex	NULL
and	NULL
the	NULL
abundance	NULL
of	NULL
this	NULL
activity	NULL
was	NULL
increased	NULL
by	NULL
stimulation	NULL
.	NULL

Similar	NULL
pat	NULL
A	NULL
Normal	NULL
PBL	NULL
RCC	NULL
PBL	NULL
23	NULL
PMA/lonomycin	NULL
0	NULL
0.5	NULL
2.0	NULL
0	NULL
0.5	NULL
2.0	NULL
(	NULL
Hr	NULL
)	NULL
«	NULL
o	NULL
«	NULL
a	NULL
wo	NULL
was	NULL
am	NULL
.	NULL

q-	NULL
CRE	NULL
>	NULL
Meee	NULL
Cus	NULL
ai	NULL
<	NULL
-	NULL
RelA	NULL
§	NULL
for	NULL
-	NULL
as	NULL
ams	NULL
«	NULL
»	NULL
-	NULL
--	NULL
NFkB	NULL
i	NULL
was	NULL
hee	NULL
eae	NULL
wa	NULL
mas	NULL
ms	NULL
q	NULL
CRE	NULL
!	NULL

9	NULL
_	NULL
an	NULL
T2	NULL
es	NULL
-	NULL
»	NULL
-	NULL
G-	NULL
Rela	NULL
8	NULL
&	NULL
wi	NULL
we	NULL
«	NULL
«	NULL
»	NULL
-_	NULL
CB	NULL
we	NULL
--	NULL
-	NULL
<	NULL
-	NULL
NFBI	NULL
§	NULL
B	NULL
Normal	NULL
PBL	NULL
RCC	NULL
PBL	NULL
18	NULL
PMA/lonomycin	NULL
0	NULL
0.5	NULL
1.0	NULL
2.0	NULL
0	NULL
0.5	NULL
1.0	NULL
2.0	NULL
(	NULL
Hr	NULL
)	NULL
-	NULL
sew	NULL
<	NULL
a	NULL
>	NULL
sme	NULL
-e-	NULL
c-Rel	NULL
z	NULL
=	NULL
o	NULL
me	NULL
mae	NULL
ame	NULL
-	NULL
<	NULL
-	NULL
RelA	NULL
|	NULL
@	NULL
&	NULL
-	NULL
we	NULL
c	NULL
»	NULL
«	NULL
o	NULL
-	NULL
cs	NULL
»	NULL
P	NULL
@	NULL
pame	NULL
--	NULL
NFcBI	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Altered	NULL
nuclear	NULL
translocation	NULL
of	NULL
RelA	NULL
and	NULL
c-Rel	NULL
showed	NULL
in	NULL
patient	NULL
T	NULL
cells	NULL
.	NULL

301	NULL
Table	NULL
1	NULL
.	NULL

«	NULL
B/Rel	NULL
protein	NULL
expression	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
in	NULL
N-PBL	NULL
,	NULL
P-PBL	NULL
and	NULL
N-PBL	NULL
with	NULL
RCC-S	NULL
Expression	NULL
&	NULL
N-PBL	NULL
P-PBL	NULL
N-PBL+RCC-S	NULL
activity	NULL
(	NULL
n=5	NULL
)	NULL
(	NULL
n=10	NULL
)	NULL
(	NULL
n=10	NULL
)	NULL
+	NULL
5	NULL
-	NULL
6	NULL
6	NULL
+/-	NULL
4	NULL
4	NULL
N-PBL	NULL
,	NULL
normal	NULL
T	NULL
cells	NULL
;	NULL
P-PBL	NULL
,	NULL
T	NULL
cells	NULL
of	NULL
RCC	NULL
patient	NULL
;	NULL
RCC-S	NULL
,	NULL
supernatant	NULL
from	NULL
RCC	NULL
explants	NULL
terns	NULL
of	NULL
response	NULL
were	NULL
observed	NULL
when	NULL
normal	NULL
and	NULL
patient	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
anti-CD3/IL-2	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
and	NULL
1xBa	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
The	NULL
nuclear	NULL
localization	NULL
of	NULL
RelA	NULL
,	NULL
c-Rel	NULL
and	NULL
NF-4B1	NULL
in	NULL
the	NULL
different	NULL
cell	NULL
populations	NULL
was	NULL
examined	NULL
by	NULL
Western	NULL
analysis	NULL
of	NULL
cytoplasmic	NULL
and	NULL
nuclear	NULL
extracts	NULL
at	NULL
various	NULL
times	NULL
following	NULL
stimulation	NULL
.	NULL

In	NULL
normal	NULL
T	NULL
cells	NULL
,	NULL
expression	NULL
of	NULL
c-Rel	NULL
,	NULL
RelA	NULL
and	NULL
was	NULL
increased	NULL
in	NULL
the	NULL
nucleus	NULL
after	NULL
30	NULL
min	NULL
and	NULL
two	NULL
hr	NULL
of	NULL
stimulation	NULL
.	NULL

There	NULL
were	NULL
decreased	NULL
expression	NULL
of	NULL
RelA	NULL
and	NULL
c-Rel	NULL
in	NULL
the	NULL
nuclei	NULL
of	NULL
patient	NULL
T	NULL
cells	NULL
suggesting	NULL
impaired	NULL
translocation	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Alterations	NULL
in	NULL
levels	NULL
of	NULL
nuclear	NULL
RelA	NULL
were	NULL
the	NULL
most	NULL
dramatic	NULL
.	NULL

In	NULL
four	NULL
of	NULL
10	NULL
RCC	NULL
patient	NULL
T	NULL
cells	NULL
modest	NULL
but	NULL
significant	NULL
levels	NULL
of	NULL
RelA	NULL
were	NULL
detected	NULL
within	NULL
the	NULL
nucleus	NULL
after	NULL
30	NULL
min	NULL
of	NULL
stimulation	NULL
but	NULL
faded	NULL
into	NULL
the	NULL
background	NULL
in	NULL
two	NULL
hr	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

In	NULL
six	NULL
other	NULL
samples	NULL
nuclear	NULL
RelA	NULL
was	NULL
undetectable	NULL
at	NULL
any	NULL
time	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Levels	NULL
of	NULL
NF-	NULL
«	NULL
kB1	NULL
and	NULL
c-Rel	NULL
in	NULL
the	NULL
nucleus	NULL
were	NULL
increased	NULL
modestly	NULL
following	NULL
stimulation	NULL
.	NULL

Interest-ingly	NULL
,	NULL
no	NULL
C1	NULL
activity	NULL
was	NULL
seen	NULL
under	NULL
these	NULL
conditions	NULL
.	NULL

T	NULL
cells	NULL
from	NULL
normal	NULL
donors	NULL
and	NULL
RCC	NULL
patients	NULL
were	NULL
stimulated	NULL
for	NULL
various	NULL
times	NULL
with	NULL
PMA/ionomycin	NULL
to	NULL
determine	NULL
the	NULL
change	NULL
in	NULL
IxBa	NULL
@	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
NF-KB	NULL
activity	NULL
,	NULL
by	NULL
Western	NULL
analysis	NULL
.	NULL

A	NULL
characteristic	NULL
decrease	NULL
in	NULL
I1xBa	NULL
expression	NULL
was	NULL
observed	NULL
within	NULL
30	NULL
min	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
which	NULL
coincides	NULL
with	NULL
the	NULL
nuclear	NULL
appearance	NULL
of	NULL
RelA	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

In	NULL
patient-derived	NULL
T	NULL
cells	NULL
(	NULL
n=10	NULL
)	NULL
,	NULL
the	NULL
magnitude	NULL
and	NULL
kinetics	NULL
of	NULL
IxBa	NULL
@	NULL
degradation	NULL
were	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
normal	NULL
T	NULL
cells	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
demonstrate	NULL
that	NULL
early	NULL
events	NULL
in	NULL
NF-KB	NULL
acti-	NULL
Normal	NULL
PBL	NULL
RCC	NULL
PBL26	NULL
_	NULL
RCC	NULL
PBL	NULL
25	NULL
PMA/lonomycin	NULL
0	NULL
0.25	NULL
0.5	NULL
2.0	NULL
40	NULL
0	NULL
0.25	NULL
05	NULL
2.0	NULL
40	NULL
0	NULL
0.25	NULL
0.5	NULL
20	NULL
(	NULL
Hr	NULL
)	NULL
-	NULL
<	NULL
-	NULL
IkBa	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Normal	NULL
degradation	NULL
of	NULL
IkBa	NULL
following	NULL
stimulation	NULL
is	NULL
observed	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
and	NULL
patient	NULL
T	NULL
cells	NULL
.	NULL

302	NULL
Table	NULL
2	NULL
.	NULL

Degradation	NULL
of	NULL
IxBa	NULL
in	NULL
N-PBL	NULL
,	NULL
P-PBL	NULL
and	NULL
N-PBL	NULL
with	NULL
RCC-S	NULL
Degradation	NULL
N-PBL	NULL
P-PBL	NULL
N-PBL+RCC-S	NULL
°	NULL
(	NULL
n=5	NULL
)	NULL
(	NULL
n=10	NULL
)	NULL
(	NULL
n=10	NULL
)	NULL
+	NULL
5	NULL
10	NULL
8	NULL
_	NULL
2	NULL
Abbreviations	NULL
are	NULL
as	NULL
noted	NULL
in	NULL
Table	NULL
1	NULL
vation	NULL
are	NULL
normal	NULL
in	NULL
patient	NULL
T	NULL
cells	NULL
.	NULL

Effect	NULL
of	NULL
RCC-S	NULL
in	NULL
NF-zB	NULL
activation	NULL
Normal	NULL
T	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
RCC-S	NULL
overnight	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
PMA/ionomycin	NULL
to	NULL
determine	NULL
whether	NULL
RCC-S	NULL
could	NULL
alter	NULL
activation	NULL
of	NULL
NF-KB	NULL
in	NULL
not-mal	NULL
T	NULL
cells	NULL
NF-	NULL
«	NULL
B	NULL
proteins	NULL
remained	NULL
in	NULL
the	NULL
cytoplasm	NULL
but	NULL
failed	NULL
to	NULL
undergo	NULL
nuclear	NULL
translocation	NULL
after	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

kB-binding	NULL
activity	NULL
was	NULL
also	NULL
suppressed	NULL
by	NULL
RCC-S	NULL
as	NULL
determined	NULL
by	NULL
EMSA	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

In	NULL
most	NULL
cases	NULL
(	NULL
n=8	NULL
)	NULL
,	NULL
RCC-S	NULL
did	NULL
not	NULL
alter	NULL
the	NULL
normal	NULL
degradation	NULL
of	NULL
IkBa	NULL
@	NULL
.	NULL

In	NULL
a	NULL
few	NULL
experiments	NULL
(	NULL
n=2	NULL
)	NULL
,	NULL
the	NULL
degradation	NULL
of	NULL
IkBa	NULL
@	NULL
was	NULL
reduced	NULL
by	NULL
RCC-S	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

This	NULL
frequency	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
observed	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patient	NULL
(	NULL
n=10	NULL
)	NULL
.	NULL

A	NULL
Normal	NULL
PBL	NULL
RCC-S	NULL
PMA/lonomycin	NULL
0	NULL
025	NULL
05	NULL
20	NULL
40	NULL
0	NULL
025	NULL
05	NULL
20	NULL
40	NULL
(	NULL
Hr	NULL
)	NULL
_	NULL
_	NULL
___	NULL
c-Rel	NULL
z	NULL
*-	NULL
==	NULL
=-	NULL
-	NULL
*	NULL
--	NULL
RelA	NULL
:	NULL
|	NULL
‘	NULL
E_	NULL
,	NULL
3	NULL
we	NULL
amw	NULL
ous	NULL
cns	NULL
cre	NULL
>	NULL
<	NULL
ee	NULL
=f	NULL
--	NULL
NFxBI	NULL
&	NULL
_____	NULL
sen	NULL
-	NULL
___	NULL
c-Rel	NULL
as	NULL
on	NULL
da	NULL
ow	NULL
oo	NULL
om	NULL
an	NULL
op	NULL
--	NULL
-=	NULL
~-	NULL
RelA	NULL
2	NULL
O	NULL
-e	NULL
as	NULL
am	NULL
ow	NULL
-	NULL
|	NULL
c=	NULL
as	NULL
ew	NULL
ee	NULL
en	NULL
0	NULL
<	NULL
--	NULL
|G	NULL
3	NULL
-	NULL
-	NULL
-	NULL
-	NULL
--	NULL
IkBa	NULL
B	NULL
Normal	NULL
PBL	NULL
RCC-S	NULL
PMA/lonomycin	NULL
0	NULL
0.25	NULL
05	NULL
(	NULL
Hr	NULL
)	NULL
:	NULL
=	NULL
yb	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

RCC-S	NULL
suppresses	NULL
the	NULL
activation	NULL
of	NULL
NFkB	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Western	NULL
blot	NULL
.	NULL

RCC-S	NULL
inhibits	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
RelA	NULL
,	NULL
c-Rel	NULL
and	NULL
NF	NULL
«	NULL
BA1	NULL
.	NULL

The	NULL
degradation	NULL
of	NULL
|	NULL
xBa	NULL
occurs	NULL
normally	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
exposed	NULL
to	NULL
RCC-S	NULL
in	NULL
some	NULL
experiments	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EMSA	NULL
:	NULL
RCC-S	NULL
suppressed	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

20	NULL
40	NULL
0	NULL
025	NULL
05	NULL
20	NULL
40	NULL
H.J	NULL
.	NULL

Kim	NULL
,	NULL
J.K.	NULL
Park	NULL
,	NULL
Y.G	NULL
.	NULL

Kim	NULL
DISCUSSION	NULL
The	NULL
development	NULL
of	NULL
cellular	NULL
immunity	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

Activation-dependent	NULL
stimulation	NULL
of	NULL
new	NULL
gene	NULL
transcription	NULL
is	NULL
now	NULL
well	NULL
documented	NULL
,	NULL
involving	NULL
transacting	NULL
factors	NULL
such	NULL
as	NULL
NF-	NULL
«	NULL
B	NULL
which	NULL
regulates	NULL
the	NULL
expression	NULL
of	NULL
many	NULL
genes	NULL
important	NULL
to	NULL
T	NULL
cell	NULL
function	NULL
and	NULL
growth	NULL
(	NULL
6	NULL
,	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

T	NULL
cells	NULL
from	NULL
cancer	NULL
patients	NULL
of	NULL
tumor-bearing	NULL
animals	NULL
are	NULL
impaired	NULL
in	NULL
theif	NULL
response	NULL
to	NULL
extracellular	NULL
stimuli	NULL
including	NULL
the	NULL
activation	NULL
of	NULL
DNA-binding	NULL
activity	NULL
(	NULL
14	NULL
,	NULL
18	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
show	NULL
that	NULL
there	NULL
are	NULL
alterations	NULL
in	NULL
both	NULL
the	NULL
expression	NULL
and	NULL
DNA-binding	NULL
activity	NULL
of	NULL
NF-4B	NULL
family	NULL
members	NULL
of	NULL
RCC	NULL
patient	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
major	NULL
inducible	NULL
<	NULL
B-specific	NULL
binding	NULL
complex	NULL
(	NULL
C1	NULL
)	NULL
either	NULL
did	NULL
not	NULL
appear	NULL
in	NULL
the	NULL
nucleus	NULL
of	NULL
was	NULL
modestly	NULL
activated	NULL
and	NULL
exhibited	NULL
a	NULL
markedly	NULL
reduced	NULL
time	NULL
course	NULL
.	NULL

The	NULL
failure	NULL
of	NULL
c-Rel	NULL
and	NULL
RelA	NULL
to	NULL
accumulate	NULL
normally	NULL
in	NULL
the	NULL
nuclei	NULL
of	NULL
patient	NULL
T	NULL
cells	NULL
was	NULL
due	NULL
to	NULL
an	NULL
event	NULL
occurring	NULL
after	NULL
phosphorylation	NULL
and	NULL
degradation	NULL
of	NULL
the	NULL
inhibitor	NULL
1xBq	NULL
since	NULL
this	NULL
latter	NULL
process	NULL
occurred	NULL
normally	NULL
in	NULL
RCC	NULL
patient	NULL
T	NULL
cells	NULL
.	NULL

Although	NULL
the	NULL
biological	NULL
nature	NULL
of	NULL
the	NULL
soluble	NULL
products	NULL
in	NULL
tumor	NULL
supernatants	NULL
is	NULL
not	NULL
known	NULL
,	NULL
the	NULL
culture	NULL
supernatant	NULL
of	NULL
tumor	NULL
cells	NULL
may	NULL
produce	NULL
a	NULL
variety	NULL
of	NULL
immuno-suppressive	NULL
molecules	NULL
such	NULL
as	NULL
IL-10	NULL
,	NULL
TGF-	NULL
and	NULL
prosta-glandin	NULL
E2	NULL
(	NULL
5	NULL
)	NULL
.	NULL

They	NULL
may	NULL
contribute	NULL
to	NULL
immune	NULL
unresponsiveness	NULL
of	NULL
cancer	NULL
patients	NULL
and	NULL
inhibit	NULL
the	NULL
activation	NULL
of	NULL
NF-kB	NULL
.	NULL

Our	NULL
results	NULL
demonstrate	NULL
that	NULL
RCC-S	NULL
can	NULL
induce	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
the	NULL
same	NULL
phenotype	NULL
of	NULL
impaired	NULL
NF-KB	NULL
activation	NULL
that	NULL
is	NULL
detected	NULL
in	NULL
T	NULL
cells	NULL
of	NULL
RCC	NULL
patient	NULL
.	NULL

These	NULL
alterations	NULL
in	NULL
NF-4B	NULL
activity	NULL
may	NULL
be	NULL
due	NULL
to	NULL
a	NULL
product	NULL
(	NULL
s	NULL
)	NULL
of	NULL
renal	NULL
tumor	NULL
cells	NULL
.	NULL

Stimulus-dependent	NULL
degradation	NULL
of	NULL
IxBa	NULL
in	NULL
the	NULL
cytoplasm	NULL
was	NULL
not	NULL
impaired	NULL
by	NULL
RCC-S	NULL
in	NULL
most	NULL
experiments	NULL
.	NULL

However	NULL
,	NULL
the	NULL
degradation	NULL
of	NULL
IkBa	NULL
was	NULL
reduced	NULL
by	NULL
RCC-S	NULL
in	NULL
two	NULL
out	NULL
of	NULL
10	NULL
cases	NULL
.	NULL

Thus	NULL
,	NULL
there	NULL
appears	NULL
to	NULL
be	NULL
at	NULL
least	NULL
two	NULL
different	NULL
mechanisms	NULL
by	NULL
which	NULL
RCC-S	NULL
can	NULL
suppress	NULL
NF-4B	NULL
acti-vation	NULL
.	NULL

First	NULL
,	NULL
NF-KB	NULL
proteins	NULL
do	NULL
not	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
at	NULL
all	NULL
.	NULL

Second	NULL
,	NULL
NF-4B	NULL
proteins	NULL
degrade	NULL
in	NULL
the	NULL
nucleus	NULL
after	NULL
translocation	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
two	NULL
patterns	NULL
of	NULL
altered	NULL
activation	NULL
and	NULL
alterations	NULL
in	NULL
NF-	NULL
KB	NULL
activity	NULL
induced	NULL
by	NULL
RCC-§	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
lack	NULL
of	NULL
antitumor	NULL
immunity	NULL
in	NULL
RCC	NULL
patients	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Choudhury	NULL
M	NULL
,	NULL
Efros	NULL
M	NULL
,	NULL
Mittelman	NULL
A.	NULL
Interferons	NULL
and	NULL
inter-leukins	NULL
in	NULL
metastatic	NULL
renal	NULL
cell	NULL
carcinoma	NULL
.	NULL

Urology	NULL
1993	NULL
;	NULL
41	NULL
(	NULL
suppl	NULL
1	NULL
)	NULL
:	NULL
67-72	NULL
.	NULL

2	NULL
.	NULL

Thrasher	NULL
JB	NULL
,	NULL
Paulson	NULL
DF	NULL
.	NULL

Prognostic	NULL
factors	NULL
in	NULL
renal	NULL
cancer	NULL
.	NULL

Impaired	NULL
NF-xB	NULL
Activation	NULL
in	NULL
RCC	NULL
Patients	NULL
10	NULL
.	NULL

11	NULL
.	NULL

Urol	NULL
Clin	NULL
N	NULL
Am	NULL
1993	NULL
;	NULL
20	NULL
:	NULL
247-62.	NULL
.	NULL

Goepel	NULL
M	NULL
,	NULL
Rubben	NULL
H.	NULL
Adjuvant	NULL
therapy	NULL
in	NULL
renal	NULL
cancer	NULL
.	NULL

World	NULL
J	NULL
Urol	NULL
1991	NULL
;	NULL
9	NULL
:	NULL
232-6.	NULL
.	NULL

Sokoloff	NULL
MH	NULL
,	NULL
Figlin	NULL
RA	NULL
,	NULL
de	NULL
Kemion	NULL
JB	NULL
,	NULL
Belldegrun	NULL
AS	NULL
.	NULL

Systemic	NULL
immunotherapy	NULL
for	NULL
genitourinary	NULL
neoplasms	NULL
.	NULL

In	NULL
:	NULL
Raghavan	NULL
D	NULL
,	NULL
Scher	NULL
HI	NULL
,	NULL
Leibel	NULL
SA	NULL
,	NULL
Lange	NULL
P	NULL
,	NULL
eds	NULL
.	NULL

Principles	NULL
and	NULL
practice	NULL
of	NULL
genitourinary	NULL
oncology	NULL
.	NULL

Philadelphia	NULL
:	NULL
Lippincott-Raven	NULL
,	NULL
1997	NULL
;	NULL
869-83.	NULL
.	NULL

Ochoa	NULL
AC	NULL
,	NULL
Longo	NULL
DL	NULL
.	NULL

Alteration	NULL
of	NULL
signal	NULL
transduction	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
cancer	NULL
patients	NULL
.	NULL

In	NULL
:	NULL
DeVita	NULL
VT	NULL
,	NULL
Hellman	NULL
8	NULL
,	NULL
Rosenberg	NULL
SA	NULL
,	NULL
eds	NULL
.	NULL

Important	NULL
advances	NULL
in	NULL
oncology	NULL
.	NULL

Philadelphia	NULL
:	NULL
Lippincott-Raven	NULL
,	NULL
1995	NULL
;	NULL
43-54.	NULL
.	NULL

Nolan	NULL
GP	NULL
,	NULL
Baltimore	NULL
D.	NULL
The	NULL
inhibitory	NULL
ankyrin	NULL
and	NULL
activator	NULL
Rel	NULL
proteins	NULL
.	NULL

Current	NULL
Opinion	NULL
in	NULL
Genetics	NULL
and	NULL
Development	NULL
1992	NULL
;	NULL
2	NULL
:	NULL
211-20	NULL
,	NULL
.	NULL

Ghosh	NULL
S	NULL
,	NULL
Gifford	NULL
AB	NULL
,	NULL
Riviere	NULL
LR	NULL
,	NULL
Tempst	NULL
P	NULL
,	NULL
Nolan	NULL
GP	NULL
,	NULL
Baltimore	NULL
D.	NULL
Cloning	NULL
of	NULL
the	NULL
p50	NULL
DNA	NULL
binding	NULL
subunit	NULL
of	NULL
NF-kB	NULL
:	NULL
homology	NULL
to	NULL
rel	NULL
and	NULL
dorsal	NULL
.	NULL

Cell	NULL
1990	NULL
;	NULL
62	NULL
:	NULL
1019-29	NULL
,	NULL
.	NULL

Ruben	NULL
SM	NULL
,	NULL
Dillon	NULL
PJ	NULL
,	NULL
Schreek	NULL
R	NULL
,	NULL
Henkel	NULL
T	NULL
,	NULL
Cohen	NULL
CH	NULL
,	NULL
Maher	NULL
M	NULL
,	NULL
Bacuerle	NULL
PA	NULL
,	NULL
Rosen	NULL
CA	NULL
.	NULL

Isolation	NULL
of	NULL
a	NULL
rel-related	NULL
cDNA	NULL
that	NULL
potentially	NULL
encodes	NULL
the	NULL
65-KD	NULL
subunit	NULL
of	NULL
NF-	NULL
gB	NULL
.	NULL

Science	NULL
1991	NULL
;	NULL
251	NULL
:	NULL
1490-3.	NULL
.	NULL

Neri	NULL
A	NULL
,	NULL
Chang	NULL
CC	NULL
,	NULL
Lombartdi	NULL
L	NULL
,	NULL
Salina	NULL
M	NULL
,	NULL
Corradini	NULL
P	NULL
,	NULL
Maiolo	NULL
AT	NULL
,	NULL
Chaganti	NULL
RS	NULL
,	NULL
Dalla-Favera	NULL
R.	NULL
B	NULL
cell	NULL
lymphoma-associated	NULL
chromosomal	NULL
translocation	NULL
involves	NULL
candidate	NULL
oncogene	NULL
lyt-10	NULL
,	NULL
homologous	NULL
to	NULL
NF-kB	NULL
p50	NULL
.	NULL

Cell	NULL
1991	NULL
;	NULL
67	NULL
:	NULL
1075-87	NULL
.	NULL

Ryseck	NULL
RP	NULL
,	NULL
Bull	NULL
P	NULL
,	NULL
Takamiya	NULL
M	NULL
,	NULL
Bours	NULL
V	NULL
,	NULL
Siebelist	NULL
U	NULL
,	NULL
Dobrzanski	NULL
P	NULL
,	NULL
Bravo	NULL
R.	NULL
RelB	NULL
,	NULL
a	NULL
new	NULL
Rel	NULL
family	NULL
transcription	NULL
activator	NULL
that	NULL
can	NULL
interact	NULL
with	NULL
DNA	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
1992	NULL
;	NULL
12	NULL
:	NULL
674-84	NULL
.	NULL

Gilmore	NULL
TD	NULL
,	NULL
Morin	NULL
PJ	NULL
.	NULL

The	NULL
IxB	NULL
proteins	NULL
:	NULL
members	NULL
of	NULL
multi-	NULL
12	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

303	NULL
functional	NULL
family	NULL
.	NULL

Trends	NULL
in	NULL
Genetics	NULL
1993	NULL
;	NULL
9	NULL
:	NULL
427-33	NULL
.	NULL

Henkel	NULL
T	NULL
,	NULL
Machleidt	NULL
T	NULL
,	NULL
Alkalay	NULL
I	NULL
,	NULL
Kronke	NULL
M	NULL
,	NULL
Ben-Neiah	NULL
Y	NULL
,	NULL
Basuerle	NULL
PA	NULL
.	NULL

Rapid	NULL
proteolysis	NULL
of	NULL
IxBa	NULL
is	NULL
necessary	NULL
for	NULL
activation	NULL
of	NULL
transcription	NULL
factor	NULL
NFxB	NULL
.	NULL

Nature	NULL
1993	NULL
;	NULL
365	NULL
:	NULL
182-5.	NULL
.	NULL

Finke	NULL
JH	NULL
,	NULL
Zea	NULL
AH	NULL
,	NULL
Stanley	NULL
J	NULL
,	NULL
Longo	NULL
DL	NULL
,	NULL
Mizoguchi	NULL
H	NULL
,	NULL
Tubbs	NULL
RR	NULL
,	NULL
Wiltrout	NULL
JJ	NULL
,	NULL
O'Shea	NULL
JJ	NULL
,	NULL
Kudoh	NULL
S	NULL
,	NULL
Klein	NULL
E	NULL
,	NULL
Bukowski	NULL
RM	NULL
,	NULL
Ochoa	NULL
AC	NULL
.	NULL

Loss	NULL
of	NULL
T-cell	NULL
receptor	NULL
&	NULL
chain	NULL
and	NULL
p56	NULL
in	NULL
T-cell	NULL
infiltrating	NULL
human	NULL
renal	NULL
cell	NULL
carcinoma	NULL
.	NULL

Cancer	NULL
Res	NULL
1993	NULL
;	NULL
53	NULL
:	NULL
5613-6	NULL
.	NULL

Li	NULL
X	NULL
,	NULL
Liu	NULL
J	NULL
,	NULL
Park	NULL
JK	NULL
,	NULL
Hamilton	NULL
TA	NULL
,	NULL
Rayman	NULL
P	NULL
,	NULL
Klein	NULL
E	NULL
,	NULL
Edinger	NULL
M	NULL
,	NULL
Tubbs	NULL
R	NULL
,	NULL
Bukowski	NULL
R	NULL
,	NULL
Finke	NULL
J.	NULL
T	NULL
cells	NULL
from	NULL
renal	NULL
cell	NULL
carcinoma	NULL
patients	NULL
exhibit	NULL
an	NULL
abnormal	NULL
pattern	NULL
of	NULL
5B-specific	NULL
DNA-binding	NULL
activity	NULL
:	NULL
a	NULL
preliminary	NULL
report	NULL
.	NULL

Cancer	NULL
Res	NULL
1994	NULL
;	NULL
54	NULL
:	NULL
5424-9	NULL
,	NULL
Schreiber	NULL
E	NULL
,	NULL
Matthias	NULL
E	NULL
,	NULL
Mullet	NULL
MM	NULL
,	NULL
Schaffner	NULL
W.	NULL
Rapid	NULL
detection	NULL
of	NULL
octamer	NULL
binding	NULL
proteins	NULL
with	NULL
``	NULL
Mini-extracts	NULL
``	NULL
prepared	NULL
from	NULL
a	NULL
small	NULL
number	NULL
of	NULL
cells	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
1989	NULL
;	NULL
7	NULL
:	NULL
6419-23	NULL
.	NULL

Ullman	NULL
KS	NULL
,	NULL
Northrop	NULL
JP	NULL
,	NULL
Verweij	NULL
CL	NULL
,	NULL
Crabtree	NULL
GR	NULL
.	NULL

Transmission	NULL
of	NULL
signals	NULL
from	NULL
the	NULL
T	NULL
lymphocyte	NULL
antigen	NULL
receptor	NULL
to	NULL
the	NULL
genes	NULL
responsible	NULL
for	NULL
cell	NULL
proliferation	NULL
and	NULL
immune	NULL
func-tion	NULL
:	NULL
the	NULL
missing	NULL
link	NULL
Ann	NULL
Rev	NULL
Immunol	NULL
1990	NULL
;	NULL
8	NULL
:	NULL
421-52	NULL
.	NULL

Sen	NULL
R	NULL
,	NULL
Baltimore	NULL
D.	NULL
Multiple	NULL
nuclear	NULL
factors	NULL
interact	NULL
with	NULL
the	NULL
immunoglobulin	NULL
enhancer	NULL
sequences	NULL
.	NULL

Cell	NULL
1986	NULL
;	NULL
46	NULL
:	NULL
705-16	NULL
.	NULL

Ghosh	NULL
P	NULL
,	NULL
Sica	NULL
A	NULL
,	NULL
Young	NULL
HA	NULL
,	NULL
Ye	NULL
J	NULL
,	NULL
Franco	NULL
JL	NULL
,	NULL
Wiltrout	NULL
RH	NULL
,	NULL
Longo	NULL
DL	NULL
,	NULL
Rice	NULL
NR	NULL
,	NULL
Komschlies	NULL
KL	NULL
.	NULL

Alterations	NULL
in	NULL
NFgxB/	NULL
Rel	NULL
family	NULL
proteins	NULL
in	NULL
splenic	NULL
T-cells	NULL
from	NULL
tumor-bearing	NULL
mice	NULL
and	NULL
reversal	NULL
following	NULL
therapy	NULL
.	NULL

Cancer	NULL
Res	NULL
1994	NULL
;	NULL
54	NULL
;	NULL
2969-72	NULL
.	NULL

